

## **ALLEGATO B**

### **UNIVERSITÀ DEGLI STUDI DI MILANO**

selezione pubblica per n. 1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale 06/D2 - Endocrinologia, Nefrologia e Scienze della Alimentazione e del Benessere, settore scientifico-disciplinare MED/13 - Endocrinologia presso il Dipartimento di Scienze Cliniche e di Comunità, (avviso bando pubblicato sulla G.U. n. 31 del 21/04/2023) Codice concorso 5385.

Alessandra Petrelli  
**CURRICULUM VITAE**

### **INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)**

COGNOME	PETRELLI
NOME	ALESSANDRA
DATA DI NASCITA	29, agosto, 1982

### **TITOLI**

- 26/09/2007: **Laurea in Medicina e Chirurgia**, Università Vita-Salute San Raffaele, Milano.  
Votazione: 110/110 cum laude
- 28/03/2013: **Specializzazione in Medicina Interna**, Università Vita-Salute San Raffaele, Milano.  
Votazione: 70/70 cum laude
- 20/04/2017: **PhD in Infection and Immunity**, Universiteit Utrecht, Utrecht, Paesi Bassi

### **CONTRATTI DI RICERCA**

- **University Medical Center Utrecht** a partire dal 01-01-2013 fino al 15-09-2016
- **Università Vita-Salute San Raffaele** a partire dal 01-11-2016 fino al 31-08-2017
- **IRCCS Ospedale San Raffaele** a partire dal 01-09-2018 fino al 31-08-2019
- **Fondazione Centro San Raffaele** a partire dal 01-03-2020 fino al 30-11-2021
- **IRCCS Ospedale San Raffaele** a partire dal 01-12-2021 fino ad oggi.

### **DIDATTICA:**

- Anno accademico 2022 - 2023: **Professore a contratto**, Endocrinologia e Malattie del Ricambio, Corso di laurea in Medicina (12 ore) e International Medical Doctor Program (14 ore), Università Vita-Salute San Raffaele, Milano, IT
- 
- 21/09/2018: Conseguitamento **Abilitazione Scientifica Nazionale Professore di 2ª Fascia**, in **MED/13** Endocrinologia, nefrologia e scienze dell'alimentazione e del Benessere (Settore concorsuale 06/D2).

## ATTIVITÀ DI RICERCA PRESSO QUALIFICATI ISTITUTI ITALIANI O STRANIERI:

- 05/2020-presente, **Project Leader** del Tissue & Systemic Immunity Lab, Diabetes Research Institute, Milano, IT
- 11/2016-04/2020, **Postdoctoral Fellow** presso Immune Mediated Diseases Unit, Diabetes Research Institute, Milano, IT
- 01/2013-09/2016, **Researcher** presso il Laboratory of Translational Immunology, UMC Utrecht, Paesi Bassi
- 08/2011-12/2012, **Research Fellow** presso l'Immune Tolerance Unit, Diabetes Research Institute, Milano, IT
- 08/2009-09/2010, **Research Fellow** presso il Transplant Research Center, Harvard Medical School, Boston (MA), USA

## ATTIVITÀ IN CAMPO CLINICO:

- 01-02-2022-presente **Consulente** presso U.O. Endocrinologia, IRCCS Ospedale San Raffaele, Milano

## REALIZZAZIONE DI ATTIVITÀ PROGETTUALE:

Finanziamenti ottenuti in qualità di **Principal Investigator**:

1. AXA Postdoctoral Fellowship (2016-2018, 130.000 EUR)
2. Marie-Skłodowska Curie Individual Fellowship (2017-2019, 180.000 EUR) "Immunometabolism in human obesity"
3. JDRF Postdoctoral Fellowship (#3-PDF-2016-187-A-N) (2016, 160.000 EUR) "Neutrophils and T1D: a neglected liaison in disease pathogenesis?". Rinuncia per sovrapposizione di grants
4. JDRF Advanced Postdoctoral Fellowship (#3-APF-2019-744-A-N) (2020-2023, 230.000 EUR) "Insulin-resistance and autoimmunity: the tale of an endotype in T1D"
5. Italian Ministry of Health-Ricerca Finalizzata, Young Researchers grant (GR-2019-12368679) (2021-2024, 450.000 EUR) "Investigation of CD8 T cell-mediated mechanisms of insulin-resistance in human obesity and type 2 diabetes".
6. Fondazione Italiana Diabete (FID), "Unravelling T1D-endotypes: the Paediatric Autoimmunity and Diabetes study" (2022-2023, 18.000 euros).

Finanziamenti ottenuti in qualità di **collaboratore**:

1. Subaward JDRF-SRA (PI: Eddie James) "Probing the role of neutrophil activity in the pathogenesis of type 1 diabetes" (1-SRA-2019-809-S-B); Role: key personnel (2019-2021, 42.000 EUR)
2. Partnership con Dompè pharma (PI: L. Piemonti); Role: Head of central laboratory (2021-2023: 300.000 euro)

## ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI

- 2023-presente: nPOD-Principal investigator per il Progetto "Unraveling the Role of CD45RA+CCR7+CD4 T Cells in the Pathogenesis of Type 1 Diabetes".
- 2017-presente: Collaborator in TrialNet (<https://www.trialnet.org>).
- 2013-2016 Ricercatore selezionato per Innovative Training Network (ITN) Eutrain (<http://eutrain-network.eu>), Marie Skłodowska-Curie Actions, UMCU, Utrecht, Paesi Bassi.

## INVITED SPEAKER A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI

1. Invito per il seminario dal titolo “Insulin resistance as Predictor of Progression to Type 1 Diabetes in Autoantibody-Positive Relatives” agli incontri mensili di INNODIA HARVEST WP3 il December 13<sup>th</sup> 2023.
2. Invito per seminario su “Immunoterapia del Diabete di tipo 1” al Congresso Milano Diabete, Milano, 15/12/2023.
3. Seminario presso Università degli Studi di Milano, “A journey in search of diabetes endotypes”, 12/06/2023
4. European Consortium Nutrisheld: “The impact of diet and microbiome on systemic inflammation in obese children”, 04/11/2021
5. TrialNet Steering Committee virtual meeting, “Platelet-neutrophil aggregates characterize the development of Type 1 diabetes in humans and NOD mice”, 05/10/2021
6. Scuola di Perfezionamento in endocrinologia e diabetologia pediatrica (SIEDP) 30/04/21, for the talk “Autoimmunità e danno endocrino: meccanismi patogenetici e markers di malattia”
7. Milan Meets Immunology (MMI), career talk: ‘The good, the bad and the oddities of my career choices’, 19 Feb 2019
8. TrialNet Steering committee meeting, Reston, VA (USA), 'Define immunological, genetic and metabolic features of responders in clinical trials in new onset T1D', Marzo 2018
9. Italian Society of Pediatric Endocrinology (SIEDP), Milan: ‘How to become TrialNet participating physicians’, 15 Dicembre 2017
10. Advanced Therapy Medicinal Products congress, Valencia (Spagna), 'Treg Cell Therapy in Solid Organ Transplantation', 27-28 June 2017

## CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

1. TrialNet Emerging Leader selezionato tra TrialNet international centers (2017 - 2019)
2. Best Poster Presentation, School for Translational Immunology, Tallin, Estonia (2014)
3. Basic Science Mentee/Mentor Award, The Transplant Society 2012, Berlin, Germany (2012)
4. Young Investigator Award, IPITA Congress 2011, Pague, Czech Republic (2011)

## ORGANIZZAZIONE DI INCONTRI SCIENTIFICI

- 07/2023 Comitato organizzatore del 12<sup>th</sup> Clinical Update in Endocrinology and Metabolism
- 01/2023 Retreat della Divisione di Immunologia (DITID) dell'Ospedale San Raffaele
- 2021 - presente: Organizzatore del “Strategic Research Agenda of the Diabetes Research Institute” (DRI-SRA), seminari mensili istituzionali con 30-40 partecipanti tra ricercatori e clinici.

## ATTIVITA' EDITORIALE

- 2023 - presente: Associate Editor della rivista scientifica *Endocrine*
- 2022- presente: Revisore per l'ADA (American Diabetes Association) Research Program
- 2022 - presente: Review panel member dell'FWO, Belgio
- 2021 Guest Editor del Research Topic “Tissue-restricted Specialization of T Cells in Chronic Inflammation” for *Frontiers in Immunology*; Review editor per *Frontiers in Translational Medicine*
- 2019 - presente: Ad hoc Reviewer per *Nature Communication*, *JCI Insight*, *Diabetes*, *Clinical Immunology*, *Scientific Reports*, *Clinical & Experimental Immunology*, *Scientific Reports*, *Acta*

Diabetologica, Rheumatology.

- 2018 - 2022 Responsabile del SID-Journal Club su Immunologia del T1D.

#### **MEMBRO DI SOCIETA' SCIENTIFICHE**

2022 - presente      Membro dell'European Society of Endocrinology (ESE)  
2018 - presente      Membro dell'European Association for the Study of Diabetes (EASD)  
2018 - presente      Membro della Società Italiana di Diabetologia (SID).

#### **SUPERVISIONE DI POSTDOCTORAL FELLOWS E STUDENTI**

Postdoctoral Fellows: n.1 (2019-present); n.1 (2022- present); n.1 (2021-2022).  
Research fellows: n.1 (2021-present); n.1 (2022-present); n.1 (2020-2022).  
Medical residents: n.1 (Endocrinology, 2021-2022); n.1 (Nutritional Sciences, 2021-2022).  
Medical students: n.1 (2021-2022); n.1 (2020-2021).  
Master students: n.1 (2022-2023); n.2 (2021-2022); n.1 (2019-2020); n.1 (2018-2019); n.2 (2017-2018); n.1 (2016-2017)

#### **PUBBLICAZIONI SCIENTIFICHE**

1. Petrelli A.\*, Cugnata F., Carnovale D., Bosi E., Libman M.I., Piemonti L., Cuthbertson D., Sosenko M.J. HOMA-IR and Matsuda Index as Predictors of Progression to Type 1 Diabetes in Autoantibody-Positive Relatives. Diabetologia (accepted) \* corresponding author. IF 10.46
2. Carrera P, Marzinotto I, Bonfanti R, Massimino L, Calzavara S, Favellato M, Jofra T, De Giglio V, Bonura C, Stabilini A, Favalli V, Bondesan S, Cicalese MP, Laurenzi A, Caretto A, Frontino G, Rigamonti A, Molinari C, Scavini M, Sandullo F, Zapparoli E, Caridi N, Bonfiglio S, Castorani V, Ungaro F, Petrelli A, Barera G, Aiuti A, Bosi E, Battaglia M, Piemonti L, Lampasona V, Foustieri G. Diabetologia. 2023 Jan 24. doi: 10.1007/s00125-022-05865-5. IF 10.4
3. Mijnheer G, Servaas NH, Leong GY, Boltjes A, Spierings E, Chen P, Lai L, Petrelli A, Vastert S, de Boer RJ, Albani S, Pandit A, van Wijk F. Compartmentalization and persistence of dominant (regulatory) T cell clones indicates antigen skewing in juvenile idiopathic arthritis. Elife, 2023, doi: 10.7554/eLife.79016. IF 8.7
4. Bechi Genzano C., Bezzecchi E., Carnovale D., Mandelli A., Morotti E., Castorani V., Favalli V., Stabilini A., Insalaco V., Ragogna F., Codazzi V., Scotti G.M., Del Rosso S., Mazzi B.A., De Pellegrin M., Giustina A., Piemonti L., Bosi E., Battaglia M., Morelli M.J., Riccardo B., Petrelli A.\* Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes. Front. Immunol. 2022, doi: 10.3389/fimmu.2022.1026416 \*corresponding author IF 8.7
5. Petrelli A., Popp S.K., Fukuda R., Parish C.R., Bosi E., Simeonovic C.J. The Contribution of Neutrophils and NETs to the Development of Type 1 Diabetes. Front. Immunol., 06 July 2022, <https://doi.org/10.3389/fimmu.2022.930553>. IF 8.7
6. Popp S.K., Vecchio F., Brown D.J., Fukuda R., Suzuki Y., Takeda Y., Wakamatsu R., Sarma M.A., Garrett J., Giovenzana A., Bosi E., Lafferty A.R.A., Brown K.J., Gardiner E.E., Coupland L.A., Thomas H.E., Chong B.H., Parish C.R., Battaglia M., Petrelli A., Simeonovic C.J. Circulating platelet-neutrophil aggregates characterize the development of type 1 diabetes in humans and NOD mice, JCI Insight, 2022, DOI 10.1172/jci.insight.153993. IF 8.7
7. Giovenzana A.; Vecchio F.; Cugnata F.; Nonis A.; Mandelli A.; Stabilini A.; Mazzi B.A.; De Pellegrin M.; Laurenzi A.; Bonfanti R.; Battaglia M.; Bosi E.; Petrelli A\*. Exocrine pancreas

function is impaired in adult relatives of patients with type 1 diabetes. *Acta Diabetologica* 2021, DOI 10.1007/s00592-021-01819-2 \*corresponding author. IF 4.28

8. Petrelli A\*, Giovenzana A, Insalaco I, Philips B, Pietropaolo M, Giannoukakis N. Autoimmune inflammation and insulin resistance: Hallmarks so far and yet so close to explain diabetes endotypes. *Current Diabetes Reports* 2021 DOI 10.1007/s11892-021-01430-3 \*corresponding author. IF 4.81

9. Giovenzana A, Carnovale D, Phillips B, Petrelli A and Giannoukakis N. Neutrophils and their role in the etiopathogenesis of type 1 and type 2 diabetes. *Diabetes Metabolism Research and Reviews*. 10 July 2021 <https://doi.org/10.1002/dmrr.3483> IF 4.87

10. Voss MG, Cuthbertson DD, Cleves MM, Xu P, Evans-Molina C, Palmer JP, Redondo MJ, Steck AK, Lundgren M, Larsson H, Moore WV, Atkinson MA, Sosenko JM, Ismail HM; DPT-1 and TrialNet Study Groups. Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. *Diabetes Care*, 2021, doi: 10.2337/dc21-0226. IF 19.11

11. Mijnheer G, Lutter L, Mokry M, van der Wal M, Scholman R, Fleskens V, Pandit A, Tao W, Wekking M, Vervoort S, Roberts C, Petrelli A, Peeters JGC, Knijff M, de Roock S, Vastert S, Taams LS, van Loosdregt J & van Wijk F. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation. *Nature Communications*, 2021, <https://doi.org/10.1038/s41467-021-22975-7>. IF 17.69

12. Petrelli A., Atkinson M.A., Pietropaolo M. and Giannoukakis N. Modulation of leukocytes of the innate arm of the immune system as a potential approach to prevent the onset and progression of type 1 diabetes, *Diabetes* 2021 Feb; 70(2): 313-322. <https://doi.org/10.2337/dbi20-0026>. IF 9.46

13. Cardellini S., Socci C., Bissolati M., Pindozzi F., Giovenzana A., Saibene A., Bosi E., Battaglia M., Petrelli A\*. Enrichment of Tc1 cells and T cell resistance to suppression are associated with dysglycemia in the visceral fat of human obesity. *BMJ Open Diabetes Res Care*, 2020 Apr;8(1):e000772. doi: 10.1136/bmjdr-2019-000772 \*corresponding author. IF 3.20

14. Garavelli, S., Bruzzaniti, S., Tagliabue, E., Di Silvestre, D., Prattichizzo, F., Mozzillo, E., Fattorusso, V., La Sala, L., Ceriello, A., Puca, A.A., Mauri, P., Strollo, R., Marigliano, M., Maffei, C., Petrelli, A., Bosi, E., Franzese, A., Galgani, M., Matarese, G., de Candia, P. Plasma circulating miR-23-27-24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes. *Diabetologia* (2020) 63:2699-2712. [doi.org/10.1007/s00125-020-05237-x](https://doi.org/10.1007/s00125-020-05237-x). IF 10.46

15. Battaglia M., Ahmed S., Anderson M., Atkinson M.A., Becker D, Bingley P., Bosi E., Brusko T.M., Di Meglio L.A., Evans-Molina C., Gitelman S.E., Greenbaum C. J., Gottlieb P.A., Herold K.C., Hessner M.J., Knipp M.J., Jacobsen L., Krischer J.P., Long A.S., Lundgren M., McKinney E.F., Morgan N.G., Oram R.A., Pastinen T., Peters M.C., Petrelli A., Qian X., Redondo M.J., Roep B.O., Schatz D., Skibinski D., Peakman M. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. *Diabetes Care*, 2020 Jan;43(1):5-12. DOI: 10.2337/dc19-0880. IF 19.11

16. Vecchio F., Messina G., Giovenzana A., Petrelli A\*. New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes. *Current Diabetes Reports*. 2019 Aug 31;19(10):92. DOI: 10.1007/s11892-019-1223-5 \*corresponding author. IF 4.81

17. Battaglia M, Petrelli A, Vecchio F. Neutrophils and type 1 diabetes: current knowledge and suggested future directions. *Curr Opin Endocrinol Diabetes Obes.* 2019 Aug;26(4):201-206. DOI: 10.1097/MED.0000000000000485. IF 3.24
18. van Wijk F, Bots SH, Gohar A, Eikendal AL, Petrelli A, Zuidgeest MG, van Os-Medendorp H, van der Schaaf MF, van Sorge NM, van Wijk M, Stegeman I, Speksnijder CM, Klipstein-Grobusch K, Seyfert-Margolis V, Mollema E, den Ruijter HM. Women in translational medicine: tools to break the glass ceiling. *Frontiers in Medicine* 2018. <https://doi.org/10.3389/fmed.2018.00330>. IF 4.46
19. Petrelli A, Mijnheer G, Hoytema van Konijnenburg D, van der Wal MM, Giovannone B, Mocholi E, Vazirpanah N, Broen J.C., Hijnen D, Oldenburg B, Coffey P, Vastert SJ, Prakken BJ, Spierings E, Pandit A, Mokry M, van Wijk F. PD-1+ CD8 T cells are clonally-expanding effectors in human chronic inflammation. *Journal of Clinical Investigation* 2018 Oct 1;128(10):4669-4681. doi: 10.1172/JCI96107. IF 19.45
20. Sebastiani G, Ventriglia G, Stabilini A, Socci C, Morsiani C, Laurenzi A, Nigi L, Formichi C, Mfarrej B, Petrelli A, Foustieri G, Brusko TM, Dotta F, Battaglia M. Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Scientific Reports* 2017 Jul 31;7(1):6897. DOI: 10.1038/s41598-017-07172-1. IF 4.99
21. Petrelli A, Prakken BJ, Rosenblum ND, and EUtrain fellows. Developing Translational Medicine Professionals: the Marie Curie Actions Model. *Journal of Translational Medicine*, 2016 Nov 29;14(1):329. <https://doi.org/10.1186/s12967-016-1088-1>. IF 8.44
22. Petrelli A and van Wijk F. CD8 T cells in human autoimmune arthritis: the unusual suspects. *Nature Reviews Rheumatology*, 2016 Jul;12(7):421-8. DOI: 10.1038/nrrheum.2016.74. IF 20.54
23. Mahou R, Passemard S, Carvello M, Petrelli A, Noverraz F, Gerber-Lemaire S, Wandrey C. Contribution of polymeric materials to progress in xenotransplantation of microencapsulated cells: a review. *Xenotransplantation*, 2016 May;23(3):179-201. DOI: 10.1111/xen.12240. IF 2.89
24. Petrelli A, Wehrens EJ, Scholman RC, Prakken BJ, Vastert SJ, van Wijk F. CD8+ T cell resistance to suppression at the site of autoimmune inflammation is self-sustained and can be reversed by TNF- $\alpha$  and IFN- $\gamma$  blockade. *Arthritis & Rheumatology*, 2016 Jan;68(1):229-36. IF 15.48
25. Petrelli A, Tresoldi E, Mfarrej BJ, Paganelli A, Spotti D, Caldara R, Secchi A, Battaglia M. Generation of donor-specific T regulatory type 1 (Tr1) cells from patients on dialysis for cell therapy after kidney transplantation. *Transplantation*, 2015 Aug;99(8):1582-9. DOI: 10.1002/art.39418. IF 5.38
26. Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, Niewczas M, Bassi R, Molano RD, Kleffel S, Petrelli A, Soleti A, Ammirati E, Frigerio M, Visner G, Grassi F, Ferrero ME, Corradi D, Abdi R, Ricordi C, Sayegh MH, Pileggi A, Fiorina P. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. *Circulation*, 2013 Jan 29;127(4):463-75. DOI: 10.1161/CIRCULATIONAHA.112.123653. IF 29.69
27. Azzi J, Moore RF, Elyaman W, Mounayar M, El Haddad N, Yang S, Jurewicz M, Takakura A, Petrelli A, Fiorina P, Ruckle T, Abdi R. The Novel Therapeutic Effect of Phosphoinositide 3-Kinase- $\gamma$  Inhibitor AS605240 in Autoimmune Diabetes. *Diabetes*, 2012 Jun;61(6):1509-18. DOI: 10.2337/db11-0134. IF 9.46

28. Petrelli A, Di Fenza R, Carvello M, Gatti F, Secchi A and Fiorina P. Strategies to reverse Endothelial Progenitor Cell dysfunction in diabetes (review). *Experimental Diabetes Research*, 2012;471823. DOI: 10.1155/2012/471823. IF 4.32 (2012)
29. Carvello M\*, Petrelli A\*, Vergani A, Lee KM, Tezza S, Chin M, Orsenigo E, Staudacher C, Secchi A, Dunussi-Joannopoulos K, Sayegh MH, Markmann JF and Fiorina P. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. *Diabetes*, 2012 Jan;61(1):155-65. DOI: 10.2337/db11-0684 \*first co-authors. IF 9.46
30. Petrelli A, Carvello M, Vergani A, Lee KM, Du M, Kleffel S, Chengwen L, Mfarrej BG, Hwu P, Secchi A, Leonard W, Young D, Markmann JF, Zajac AJ and Fiorina P. IL-21 is an anti-tolerogenic cytokine of the late-phase alloimmune response. *Diabetes*, 2011 Dec;60(12):3223-34. DOI: 10.2337/db11-0880. IF 9.46
31. Fiorina P, Jurewicz M, Vergani A, Petrelli A, Carvello M, D'Addio F, Godwin JG, Law K, Wu E, Tian Z, Thoma G, Kovarik J, La Rosa S, Capella C, Rodig S, Zerwes HG, Sayegh MH, Abdi R. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. *Journal of Immunology*, 2011 Jan 1;186(1):121-31. DOI: 10.4049/jimmunol.1000799. IF 5.42
32. Petrelli A, Maestroni A, Fadini GP, Belloni D, Venturini M, Albiero M, Kleffel S, Mfarrej B, Del Maschio A, Maffi P, Avogaro A, Ferrero E, Zerbini G, Secchi A, and Fiorina P. Improved function of circulating angiogenic cells is evident in type 1 diabetic-islet transplanted patients. *American Journal of Transplantation*, 2010 Dec;10(12):2690-700. DOI: 10.1111/j.1600-6143.2010.03309.x. IF 9.36
33. Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E, Deng S, Rodig J, Ansari J, Staudacher C, Abdi R, Williams J, Markmann J, Atkinson M, Sayegh M and Fiorina P. A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice. *Diabetes*, 2010 Sep;59(9):2253-64. DOI: 10.2337/db09-1264. IF 9.46
34. Fiorina P, Vergani A, Petrelli A, D'Addio F, Monti L, Abdi R, Bosi E, Maffi P, Secchi A. Metabolic and immunological features of the failing islet transplanted patient. *Diabetes Care* 2008 Mar;31(3):436-8. DOI: 10.2337/dc07-1831. IF 19.11
35. Del Carro U, Fiorina P, Amadio S, De Toni Franceschini L, Petrelli A, Menini S, Boneschi FM, Ferrari S, Pugliese G, Maffi P, Comi G, Secchi A. Evaluation of polineuropathy markers in type 1 diabetic kidney-transplant patients and effects of islets transplantation: neurophysiological and skin biopsy longitudinal analysis. *Diabetes Care* 2007 Dec;30(12):3063-9. DOI: 10.2337/dc07-0206. IF 19.11
36. Fiorina P, Perseghin G, De Cobelli F, Gremizzi C, Petrelli A, Monti L, Maffi P, Luzi L, Secchi A, Del Maschio. Altered Kidney Graft High-Energy Phosphate Metabolism in Kidney-Transplanted End-Stage Renal Disease Type 1 Diabetic Patients: A cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation. *Diabetes Care* 2007 Mar;30(3):597-603. DOI: 10.2337/dc06-1324. IF 19.11

Data

26/09/2023

Luogo

Milano